Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Sovicell logo — Ready-to-use assay kits for plasma protein binding, membrane...

Sovicell

Ready-to-use assay kits for plasma protein binding, membrane binding and membrane permeability for ADME/Tox and DMPK

Founded 1994 Germany Leipzig, Germany 2 employees Series Unknown Total: $1.19M Biotechnology

General Information

Company Name Sovicell
Founded Year 1994
Location Germany Leipzig, Germany +1
Employees 2
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when Sovicell moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Sovicell

Sovicell GmbH is a biotechnology startup based in Germany that specializes in providing products and services for preclinical pharmaceutical research. Founded in 1994, Sovicell offers ready-to-use assay kits for plasma protein binding, membrane binding, and membrane permeability for ADME/Tox and DMPK. The company's assays, which include brain tissue binding, blood-brain barrier penetration, liver microsomal binding, and intestinal absorption, provide reliable results in less than 30 minutes. Sovicell's range of offerings also extends to boutique services for plasma protein binding studies to support reliable dose finding for first-in-man studies. The company proves to be a leader in state-of-the-art services for plasma binding and plasma displacement, including controls for plasma instability, recovery, and matrix effects in LC-MS/MS. The latest investment in Sovicell GmbH was a Venture Round investment at 14 May 2009, which was backed by MIG AG and HMW Innovations AG. Overall, Sovicell GmbH presents a promising investment opportunity in the biotechnology sector, with its innovative product offerings and strong track record in the field of preclinical pharmaceutical research.

Taxonomy: ADME/Tox, DMPK, pharmaceutical research, assay kits, plasma protein binding, tissue binding, membrane permeability, brain tissue binding, blood-brain barrier penetration, liver microsomal binding, intestinal absorption, volume of distribution, plasma binding studies, pharmacokinetic data, LC-MS/MS

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 2
Investor Investor
14 May 2009
Series D •••••• 2
Investor Investor
01 Mar 2007

FAQ About Sovicell

Ready-to-use assay kits for plasma protein binding, membrane binding and membrane permeability for ADME/Tox and DMPK
Sovicell was founded in 1994.
Sovicell is headquartered in Leipzig, Germany.
Sovicell operates in the following industries: Biotechnology.
Sovicell has approximately 2 employees.
Sovicell has completed 2 funding rounds, raising a total of $1.19M. The latest funding stage is Series Unknown.

We're actively collecting intelligence on Sovicell.

Track Sovicell to get notified

Don't just browse. Track.

Signal Tracker monitors Sovicell and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy